decisionhealth Newsletters, Part B News - 2000 Issue 9 (September)
Plan to cut drug prices meets heavy resistance in Congress
Subscribe or sign in to view the full article.
Article Overview
This article covers a congressional and administrative dispute over a federal plan affecting prices for drugs administered in physician offices and other care settings. It discusses lobbying by lawmakers, comments from federal officials, and objections from oncology stakeholders regarding payment methodology, practice expenses, and Medicare reimbursement policy. The piece is relevant to readers tracking health policy, physician payment, oncology administration issues, and federal agency actions involving drug pricing.
Why This Topic Matters
It helps readers understand a contested Medicare-related pricing policy, the political response to it, and the broader reimbursement concerns raised by clinicians and policymakers. This is useful for coding, compliance, revenue cycle, and health policy professionals monitoring federal payment changes affecting administered drugs.
What You Will Learn
- The main policy dispute involving federally administered drug pricing
- How lawmakers and agencies are positioned in the debate
- Why oncology and physician payment stakeholders are concerned about reimbursement methodology
- What broader Medicare payment and practice expense issues are being raised
Who Should Read This
- Medical coders
- Billing and reimbursement professionals
- Compliance teams
- Practice administrators
- Oncology practice managers
- Health policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com